In 1958, Health and his associates1 reported that extracts from the septal region of the brains of cattle were effective in overcoming the effects of taraxein in monkeys and in modifying certain aspects of the metabolism of schizophrenic patients. It was inferred that perhaps this septal extract could have some therapeutic significance in the treatment of schizophrenics. Four separate trials were made of this material in hospitalized schizophrenic patients.
The first trial was carried out in the spring of 1958. Five pairs of schizophrenic men and five pairs of schizophrenic women were studied. All had been ill for more than two years with no known organic disease of body or brain and had not responded to several other of the newer medications. In each pair one received a placebo, the other the extract. The patients were transferred to the research ward of the
TURNER WJ, KRUMHOLZ W, MERLIS S. Chemotherapeutic Trials in Psychosis: V. Septal Extract. Arch Gen Psychiatry. 1960;3(5):567. doi:10.1001/archpsyc.1960.01710050117013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.